Answers are grounded in this paper and cite their sources.
Review uncovers how psychedelic activation of serotonin 5-HT2A receptors drives neuroplasticity in mental disorders, highlighting therapeutic potential for neuropsychiatric conditions.
Serotonin (5-hydroxytryptamine; 5-HT) modulates a vast array of brain functions via its diverse receptor subtypes. Among these, the serotonin 5-HT2A receptor (5-HT2AR) has garnered intense recent interest for its pivotal role in mediating the effects of psychedelic compounds. Substantial evidence indicates that psychedelics act as agonists at the 5-HT2AR, triggering profound alterations in cognition, perception, and mood. These effects are hypothesized to stem from the receptor’s circuit-specific modulation of neurotransmission and its capacity to promote neuroplasticity. This review synthesizes current knowledge on the neuroanatomical distribution of 5-HT2ARs, their associated signaling pathways, and their implicated role in psychiatric pathophysiology. We further evaluate the receptor’s promise as a novel therapeutic target. While several mechanistic models are discussed, a critical outstanding challenge is the precise mapping of neural circuits that translate 5-HT2AR activation into specific behavioral outcomes. This synthesis underscores the imperative for further research to elucidate the 5-HT2AR’s role in neuropsychiatric disorders and to advance the development of targeted psychedelic-based therapies.
No takes yet. Share an insight, caveat, or question.
Asim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: